Duvelisib

What is Duvelisib?

Duvelisib is a prescription medication used in the treatment of certain blood cancers. It belongs to a class of drugs known as a PI3K inhibitor, specifically targeting the phosphoinositide 3-kinase (PI3K) delta and gamma isoforms. This mechanism allows it to selectively interfere with pathways crucial for the growth and survival of cancer cells, making it a form of targeted therapy. Duvelisib is marketed under the brand name Copiktra and is administered orally.

Approved for use in patients who have received prior treatments but whose cancer has returned or progressed, Duvelisib offers an important option for managing specific types of lymphoma and leukemia. Its development represents a significant step forward in personalized cancer medicine, focusing on the unique molecular characteristics of cancer cells rather than broad-spectrum cytotoxic effects.

How Does it Work?

The phosphoinositide 3-kinase (PI3K) pathway is a critical cell signaling network that plays a vital role in various cellular processes, including cell growth, proliferation, differentiation, and survival. In many cancers, particularly blood cancers, this pathway can become overactive, leading to uncontrolled cell growth and resistance to apoptosis (programmed cell death).

Duvelisib exerts its therapeutic effects by selectively inhibiting the PI3K-delta and PI3K-gamma isoforms. These specific isoforms are predominantly expressed in hematopoietic cells (cells that form blood components) and are often implicated in the pathogenesis of B-cell malignancies. By blocking the activity of these PI3K isoforms, Duvelisib disrupts the signaling pathways that support the survival and proliferation of malignant B-cells. This inhibition ultimately leads to a reduction in tumor cell growth and induces apoptosis in these cancerous cells, thereby helping to control the progression of the disease.

Medical Uses

Duvelisib is indicated for the treatment of adult patients with specific types of relapsed or refractory blood cancers. Its approved uses include:

• Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): For patients who have received at least two prior systemic therapies. CLL and SLL are slow-growing cancers that affect white blood cells (lymphocytes) in the blood and bone marrow, and lymph nodes, respectively.
• Relapsed or Refractory Follicular Lymphoma (FL): For patients who have received at least two prior systemic therapies. Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma that affects B-lymphocytes.

These indications highlight Duvelisib's role as a subsequent-line treatment option, offering hope for patients whose disease has progressed despite initial therapeutic attempts. The decision to use Duvelisib is typically made by an oncologist after careful consideration of the patient's medical history, prior treatments, and overall health status.

Dosage

The recommended dosage of Duvelisib is typically 25 mg taken orally twice daily. It can be taken with or without food. It is crucial for patients to take the medication exactly as prescribed by their healthcare provider and not to adjust the dose or stop treatment without consulting their doctor.

• Administration: Swallow the capsules whole. Do not open, crush, or chew the capsules.
• Missed Dose: If a dose is missed, it should be taken as soon as the patient remembers, unless it is less than 6 hours before the next scheduled dose. In that case, the missed dose should be skipped, and the patient should resume the regular dosing schedule. Do not take two doses to make up for a missed dose.
• Dose Adjustments: Dosage may need to be modified or interrupted based on the patient's tolerance and the occurrence of certain adverse reactions. Regular monitoring by a healthcare professional is essential to manage potential side effects and ensure optimal treatment efficacy.

Side Effects

Like all medications, Duvelisib can cause side effects, some of which can be serious. Patients should report any new or worsening symptoms to their healthcare provider promptly.

Common Side Effects (may affect more than 1 in 10 people):

• Diarrhea or colitis
• Skin rash
• Nausea, vomiting, abdominal pain
• Fatigue
• Fever
• Elevated liver enzymes (ALT, AST)
• Infections (e.g., pneumonia, upper respiratory tract infections)
• Neutropenia (low white blood cell count)

Serious Side Effects (require immediate medical attention):

• Severe Diarrhea/Colitis: Can be life-threatening and may require hospitalization.
• Skin Reactions: Severe skin rashes, sometimes resembling Stevens-Johnson syndrome or toxic epidermal necrolysis.
• Pneumonitis: Inflammation of the lungs, which can cause shortness of breath, cough, and fever.
• Hepatotoxicity: Liver damage, characterized by elevated liver enzymes, jaundice, and fatigue.
• Infections: Increased risk of serious and opportunistic infections due to immunosuppression.
• Neutropenia: Severe decrease in white blood cells, increasing infection risk.

Regular blood tests and close monitoring by a healthcare team are necessary to detect and manage these side effects effectively.

Drug Interactions

Duvelisib can interact with other medications, potentially altering its effectiveness or increasing the risk of adverse effects. It is crucial to inform your doctor and pharmacist about all prescription, over-the-counter, and herbal supplements you are taking.

• Strong CYP3A4 Inhibitors: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) can significantly increase Duvelisib exposure, leading to a higher risk of side effects. Dose adjustments or alternative therapies may be necessary.
• Strong CYP3A4 Inducers: Co-administration with strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John's wort) can decrease Duvelisib exposure, potentially reducing its efficacy. Concurrent use should be avoided or managed with caution.
• CYP3A4 Substrates: Duvelisib is a moderate inhibitor of CYP3A4 in the gut, which means it may increase the concentration of other drugs metabolized by this enzyme (e.g., midazolam, simvastatin, cyclosporine). Monitoring and dose adjustments for co-administered drugs may be required.
• Live Vaccines: Live attenuated vaccines should not be administered during treatment with Duvelisib due to the risk of infection in immunosuppressed patients.
• Immunosuppressants: Caution should be exercised when Duvelisib is used concurrently with other immunosuppressive agents, as this may further increase the risk of infections.

Always consult your healthcare provider before starting or stopping any new medications while on Duvelisib treatment.

FAQ

Q: Is Duvelisib a chemotherapy drug?

A: While Duvelisib is used in cancer treatment, it is not considered traditional chemotherapy. It is a targeted therapy, specifically a PI3K inhibitor, meaning it works by targeting specific molecular pathways involved in cancer cell growth, rather than broadly killing rapidly dividing cells like conventional chemotherapy.

Q: How long will I need to take Duvelisib?

A: Treatment with Duvelisib typically continues until disease progression or until unacceptable toxicity occurs. Your doctor will regularly assess your response to treatment and monitor for side effects to determine the duration of therapy.

Q: Can Duvelisib be used during pregnancy?

A: No, Duvelisib can cause harm to a fetus. Women of childbearing potential should use effective contraception during treatment and for at least one month after the last dose. Men with female partners of childbearing potential should also use effective contraception during treatment and for at least one month after the last dose.

Q: What should I do if I experience severe diarrhea while taking Duvelisib?

A: Severe diarrhea or colitis is a serious potential side effect. You should contact your doctor immediately if you experience severe or persistent diarrhea, changes in bowel habits, or blood in your stool. Your doctor may advise a temporary interruption of treatment, dose reduction, or specific medications to manage the diarrhea.

Q: How is Duvelisib different from other PI3K inhibitors?

A: Duvelisib is unique among PI3K inhibitors for its selective inhibition of both PI3K-delta and PI3K-gamma isoforms. This dual inhibition is thought to contribute to its efficacy in certain B-cell malignancies by targeting distinct but complementary pathways involved in cancer cell survival and proliferation.

Products containing Duvelisib are available through trusted online pharmacies. You can browse Duvelisib-based medications at ShipperVIP or Medicenter.

Summary

Duvelisib is an important oral antineoplastic agent approved for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. As a selective PI3K-delta and PI3K-gamma inhibitor, it represents a significant advancement in targeted therapy for these specific blood cancers. By disrupting critical signaling pathways in malignant B-cells, Duvelisib helps to control disease progression and induce cancer cell death.

While offering a valuable treatment option, it is associated with potential serious side effects, including severe diarrhea, skin reactions, and infections. Close monitoring by a healthcare professional is essential throughout treatment to manage these risks and optimize patient outcomes. Patients should maintain open communication with their medical team regarding all medications and any experienced symptoms to ensure safe and effective therapy with Duvelisib.